BrightGene Bio-Medical Technology Gets Ethics Approval for Phase 3 Trial for Blood Sugar Injection

MT NewswiresDec 5 04:49 ET

Brightgene Bio-Medical Technology Co.,Ltd. (688166.SH): BGM0504 injection indications have obtained ethical approval for Phase III clinical trials.

Ge Longhui December 4th, brightgene bio-medical technology co.,ltd. (688166.SH) announced that its wholly-owned subsidiary Brightgene New Creation Biomedical Technology (Wuxi) Co., Ltd. (referred to as "Brightgene New Creation") independently developed BGM0504 injection for lowering blood glucose indication Phase III clinical research protocol has been approved by the leading hospital Peking University People's Hospital Ethics Review Committee and obtained the "Peking University People's Hospital Ethics Review Committee Ethics Review Letter". BGM0504 injection is the company's independently developed GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) dual receptor stimulation.

Gelonghui FinanceDec 4 03:21 ET

Brightgene bio-medical technology co.,ltd. (688166.SH): Dinoprostone tablets and its active pharmaceutical ingredient, as well as the active pharmaceutical ingredient for levo-dihydroxyphenylserine, have been approved for marketing.

brightgene bio-medical technology co.,ltd. (688166.SH) announced that its wholly-owned subsidiary, brightgene pharmaceutical (suzhou) co., ltd...

Zhitong FinanceDec 3 03:16 ET

Brightgene bio-medical technology co.,ltd. (688166.SH): Subsidiary obtains pharmaceutical registration certificate and approval notice for chemical raw materials listing application.

Brightgene Bio-Medical Technology Co.,Ltd. (688166.SH) announced on December 3 that its wholly-owned subsidiary Brightgene Pharmaceutical (Suzhou) Co., Ltd. has received the "Dienogest Tablets" pharmaceutical registration certificate issued by the National Medical Products Administration, as well as the "Dienogest" and "Succinylcholine Chloride" chemical raw materials for marketing approval notification letter.

Gelonghui FinanceDec 3 03:10 ET

Is BrightGene Bio-Medical Technology (SHSE:688166) A Risky Investment?

Simply Wall StNov 29 19:39 ET

BrightGene Bio-Medical Technology's (SHSE:688166) Earnings Have Declined Over Three Years, Contributing to Shareholders 13% Loss

Simply Wall StNov 8 20:10 ET